Decoding Mitochondrial Peptides SS-31

The transcript examines the anti-aging peptide SS-31, explaining that its effectiveness depends entirely on whether an individual possesses damaged mitochondria with degraded structural fats that the compound can physically repair. While clinical trials struggled with broad physical metrics, the FDA ultimately approved the drug after observing specific leg strength improvements in patients with severe underlying conditions. The speaker emphasizes that healthy cells experience little to no benefit from the peptide, meaning that people without genuine cellular degradation will likely waste their money and feel nothing. Furthermore, users with significant mitochondrial damage frequently experience increased fatigue during the initial repair phase as the body expends energy to rebuild its cellular walls. Finally, the narrative cautions that unregulated online sourcing bypasses critical safety warnings found on the official pharmaceutical label, highlighting the importance of professional medical supervision.